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1. Introduction
Among the chapters in this monograph are those that examine the treatment of fibromyalgia 
syndrome (FMS) using nonpharmacologic natural products and other relatively novel agents 
[1–3]. Although the modes of therapy described are diverse, a role for disordered immune 
mechanisms is implicit in each of the three chapters. These include reference to sulfur springs 
considered to inhibit interleukin-2 and interferon-gamma [1], introductory explanations of 
FMS pathogenesis that invokes inflammatory dysfunction [2], and mention of inflamma-
tory cytokine production associated with autonomic nervous system dysfunction-stimulated 
microglial and astrocyte cell activation [3]. The discussion in the fourth chapter about the 
impact of FMS on the evaluation of inflammatory diseases assumes the opposite that clini-
cally significant inflammation is not a feature of FMS [4].
2. Case (should have been previously) closed
Face validity favoring a major pathogenic role for cytokine-mediated inflammation in FMS 
has been addressed in the past. Although initial reports of intermuscular fibrous tissue inflam-
mation by Stockman led Gowers to name the condition “fibrositis,” [5, 6], contemporary light 
and magnetic resonance imaging histological reports showed no evidence for peripheral mus-
cle inflammation [7, 8]. These data should have closed the book on inflammation as a promi-
nent etiopathogenic mechanism in FMS. Then along came inflammatory mediators.
In some contemporary reviews of FMS pathogenesis, inflammation is referenced in passing, 
as it is in these three chapters [9]. Whether this is done for “completeness,” after all, FMS is 
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often misclassified as a “connective tissue disease” (a misnomer), most of which are inflam-
matory in nature, or that such reference adds a sort of “scientific patina” to the discussion is 
unclear.
This review examines the validity of the concept that cytokine- and chemokine-driven inflam-
mation is relevant to the pathogenesis of FMS.
3. Background
At least three observations have been used to provide circumstantial or hypothesis-generating 
evidence to advance a role for inflammatory pathogenesis:
1. The symptoms and signs of “sickness behavior” observed in FMS can be experimentally 
induced by inflammatory cytokines [10].
2. Similar alteration of the hypothalamic–pituitary axis and autonomic nervous system ob-
served in FMS has been etiopathogenically linked to elevated inflammatory cytokines, in-
cluding interleukin-1 (IL-1), in a variety of clinical settings other than FMS [11–14].
3. Symptoms of disordered sleep, hyperalgesia, and cognitive dysfunction much like FMS 
were observed when patients with renal cell carcinoma were treated with interleukin-2 
lymphokine-activated killer (IL-2 LAK) cell therapy and when chronic hepatitis patients 
were treated with interferon alpha [15].
4. Experimental evidence for cytokine/chemokine pathogenesis
1. Previous inconsistent reports have demonstrated that C-reactive protein (CRP) can be 
marginally higher in FMS subjects than in parallel healthy controls [16]. In this analysis, 
however, serum inflammatory cytokines were not higher than in healthy controls.
2. Inconsistent elevation of a variety of serum cytokines has, however, been observed in some 
studies [16–24]. In a meta-analysis of 25 FMS studies, 1255 FMS, and 800 healthy controls 
(HC), interleukin-1 receptor antagonist (IL-1ra), interleukin-6 (IL-6), and interleukin-8 (IL-8) 
were the most likely inflammatory cytokines to be elevated [25].
Three integrated reviews, although acknowledging discrepancies in the literature, attempted 
to associate cytokine abnormalities with core FMS symptoms [26–28]. The first concluded, 
“There are discrepant findings related to whether pro-inflammatory and anti-inflammatory 
cytokines are elevated or reduced in persons with FMS and whether they correlate with core 
symptoms.” [26]. The second [27] critiqued one of the more persuasive analysis, “….. may 
have cytokine driven abnormalities to explain their pain…IL-1ra and IL-6 were significantly 
higher after stimulating PBMC of FMS patients compared to controls [29].” The results of this 
study were not corroborated in a second study [24].
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The third review of 12 separate analyses reported increased inflammatory cytokines IL-1ra, 
IL-6, and IL-8, and anti-inflammatory interleukin-10 (IL-10) or low anti-inflammatory inter-
leukin-4 (IL-4) and IL-10 [24]. Among the inflammatory chemokines also linked to signs and 
symptoms, monocyte chemoattractant protein-1 (MCP-1), eotaxin among others, were elevated.
Two potentially innovative separate controlled analyses described cytokine and chemokine 
concentrations in the supernatant after mitogen stimulation of cultured monocytes, using a 
logistical regression model to achieve statistically determined weighting for each chemokine 
and cytokine, and offered this score as diagnostic test for FMS [30, 31]. Of interest, the inflamma-
tory cytokines and chemokines including IL-6 were lower in concentration compared to healthy 
controls or individuals with autoimmune disease. These findings suggest increased damping 
control of inflammation in FMS. The authors of both these studies, however, failed to determine 
the prevalence of depression or analyze its potential effects on cytokine concentrations.
Among the most novel analyses was a report of elevation of intrathecal IL-8 derived from glia 
cells supporting the hypothesis that FMS symptoms might be mediated by glial cell activation 
through sympathetic nervous system mechanisms [32].
In summary, in individuals with FMS, peripheral blood IL-6, IL-1ra, and IL-8 concentrations 
may be a bit higher and IL-4 and IL-10 lower, and IL-8 may be relatively higher in the cerebral 
spinal fluid than in healthy controls. Inflammatory chemokines may also be higher than in 
healthy control patients.
5. Depression and inflammation
Depression and FMS are very often comorbid and show a bidirectional association [19, 33–38]. 
The prevalence of depression in FMS has been estimated to range from 20 to 80% in a detailed 
review [39]. Furthermore, the severity of comorbid depression correlates with FMS severity 
measures [40–42]. We have reported that depression, with a 73% prevalence, correlated better 
with core FMS symptoms than did any other variable in a cohort of 305 FMS patients [43].
As in FMS, similar mild elevation of CRP and inflammatory cytokines and chemokines have 
been demonstrated in depressed individuals in controlled analyses [44–53]. Many primary 
analyses of FMS inflammation [15, 30, 31, 54–56] and reviews [23, 28], however, failed to con-
trol for depression. This is an unfortunate omission.
Maes and colleagues evaluated the serum concentrations of inflammatory cytokines in rela-
tionship to depression among 21 FMS patients compared to 33 healthy controls [57].
Serum soluble gp130, an important inflammatory cytokine signal transducer, and a soluble 
interleukin-6 receptor, Il-1 ra, were significantly higher in FMS patients with a Hamilton 
Depression Rating Scale score >16 than in FMS patients with scores of 16 or lower or in healthy 
controls. In the opinion of the Menzies’ integrated review, which included the Maes analysis, 
higher inflammatory cytokines in FMS, including IL6, were related to the degree of depression, 
although inconsistencies were common [26].
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Of interest, higher body mass index partially explained cytokine differences as has been 
shown in depression [18, 52]. Therefore, inflammation in FMS, measured as higher serum 
concentrations of cytokines and chemokines, is multifactorial and not necessarily due solely 
to FMS pathophysiology.
Serum inflammatory cytokine concentrations correlate with the degree of depression and fall 
with effective treatment of depression [58]. Not surprisingly, inflammatory cytokine concentra-
tions have also been shown to correlate with pain symptoms in primary depression alone [59].
This phenomenon even occurs when the treatment is nonpharmacological, suggesting an 
intrinsic etiopathophysiologic relationship of inflammatory cytokines with depression [46]. 
This analysis also demonstrated that despite a significant fall of cytokine concentration from 
baseline, the CRP was not significantly lower.
In summary, these two analyses demonstrate a pain symptom signature integral to depres-
sion and that cytokines, while slightly higher in depression than in healthy controls, are in fact 
trivial with respect to overall inflammation measured as CRP.
6. Different process mechanisms: RA versus FMS/depression
6.1. RA
In rheumatoid arthritis (RA) comorbid FMS is associated with disproportionately higher values 
for the subjective components, patient global assessment (PtGA), and tender joint count (TJC), 
which in turn inflate the disease activity score (DAS). This phenomenon is largely mediated 
by higher patient assessed pain, fatigue, and especially poor mood, and variables that define 
the criterion, distress, and the etiopathogenesis of FMS [60–64]. As a potential explanation, 
depression alone can disproportionately increase pain sensitivity, the tender joint count (TJC), 
and a patient’s sense of wellbeing, such as PtGA in RA [19, 65]. Higher subjective signs and 
symptoms then inflate the DAS. It is important to note that concomitant FMS and depression 
in RA are not associated with obvious, clinically significant increases of CRP or erythrocyte 
sedimentation rate [42, 62, 65].
Differential response to the treatment of the so-called subjective versus objective variables is 
a hallmark of comorbid FMS and/or depression in RA. In a prospective analysis of 668 RA 
patients, 18% with comorbid FMS had higher DAS and Health Assessment Disability Index 
at baseline compared to patients without FMS [66]. The TJC and PtGA were significantly 
higher, but the objective factors, ESR, and swollen joint count (SJC) were significantly lower in 
patients with FMS compared to patients with RA alone. Achievement of low disease activity 
and remission were significantly less likely in the comorbid FMS cohort. Others have con-
firmed these observations [67].
A very instructive, early, placebo-controlled trial showed that the pain of FMS did not respond 
to the treatment with prednisone 15 mg/day [68]. So too, unlike dose-related reduction of 
objective signs in RA such as the swollen joint count (SJC) and CRP, FMS-related inflated 
subjective signs and symptoms are resistant to aggressive anti-immune, anti-inflammatory 
Discussions of Unusual Topics in Fibromyalgia4
RA treatment [69–71]. In fact, a treatment response resulting in remission in RA comorbid 
with FMS should not be expected because the higher, poorly responsive PtGA and TJC are not 
due to RA biological disease activity, but in fact to poorly responsive noninflammatory FMS 
central pain mechanisms [69].
7. Differential magnitude of inflammatory response
Mean CRP values, although reported elevated in some FMS populations compared to control 
populations, are still within the range of normal CRP [72]. Given this observation, it is both 
instructive and necessary to consider whether cytokines follow this same pattern.
7.1. Rewrite cytokine section
In RA, serum concentrations of IL-6 measured by enzyme immunoassay (ELISA) [73] in >900 
patients demonstrated mean ~ 43 pg/ml, for all, and ~54–84 pg/ml for those with active dis-
ease [55]. In another population of 66 RA patients, using a similar assay, IL-6 levels declined 
to 22.5 pg/ml in low disease activity [74].
Contrast these serum levels with serum levels in depression and FMS. Using a different more sen-
sitive ELISA assay, Grosse reported mean IL-6 serum concentration of 1.17 ± 2.59 for 214 patients 
with major depression disorder (MDD) and 0.66 ± 1.94 for healthy controls (HC) [50]. In another 
analysis of 64 MDD patients and 80 healthy controls, IL-6 levels were reported statistically higher 
in depression than in controls, 1.39 ± 0.35 versus 0.45 ± 0.28 pg/ml using yet another ELISA [47].
These same comparatively low serum levels were reported in FMS, with IL-6 in the range of 
16 pg/ml in FMS and 1 pg/ml in healthy controls using yet another ELISA assay [75]. Although 
higher than HCs, the levels are very low when compared to those in RA.
This discussion apparently shows that inflammatory cytokines, even when relatively elevated 
in FMS, are much lower than in mildly active RA. If this is true, then the elevations in FMS 
may not be sufficiently high to initiate clinical signs or symptoms. Unfortunately, as can be 
seen, diverse assays that produce diverse serum and cellular concentrations and the lack of 
control for diurnal variation make precise comparisons between diseases difficult.
Fortunately, two papers do allow comparison. The authors of both studies used very simi-
lar ELISA methods. In 16 RA patients with varying disease activity, overnight IL-6 values 
ranged from a mean of ~40 pg/ml at 11 PM to a peak of ~60 at 8 AM with large individual 
variations [76].
In FMS, although the mean values for IL-6 were statistically significantly higher in FMS 
patients than in healthy controls at night (2.94 versus 2.14 pg/ml), these serum concentrations 
were at least 10 times lower in FMS than in RA [56]. Are these meager elevations of IL-6, ~0.80 
pg/ml in FMS compared to HCs, sufficiently high enough to explain clinical differences?
Let us postulate that mildly elevated cytokines in the CNS such as IL-6 and IL-8 [32] produced 
by microglial and/or astrocyte cells are sufficient to interfere with processing and produce 
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centrally mediated pain. We are still left with the lack of clinical response to moderate daily 
prednisone and even more aggressive antirheumatic, anti-inflammatory treatments which 
have been shown to reduce inflammation due to cytokines [67, 68, 71, 77].
There is little question that FMS does associate with mild cytokine change, such as reduced 
diurnal variation of IL-6 compared to healthy individuals [56]. Forensic objectivity, how-
ever, would seem to indicate that the described modest changes in inflammatory mediators, 
whether primary or secondary, do not seem sufficient to be responsible for clinically relevant 
FMS symptoms. Furthermore, in some very legitimate contemporary hypotheses of FMS etio-
pathogenesis, there is no role for chronic cytokine-mediated processes [78, 79].
8. Conclusions
The key points from this discussion are:
1. Although a minority of studies found CRP elevated in FMS compared to healthy controls, 
the mean high value was still within the normal range.
2. Depression, which is very often comorbid with FMS, was not well controlled in many 
cytokine/chemokine analyses. When it was, it was shown to significantly contribute to 
higher cytokine values.
3. Fibromyalgia symptoms, whether as the primary diagnosis or as comorbid in RA, do not 
respond to anti-inflammatory, anti-immune therapy.
4. Both stimulated and unstimulated cytokine and chemokine studies have employed a variety 
of methods of measurements that make cytokine levels difficult to analyze between diseases. 
A few comparisons have shown relatively trivial values in FMS compared to proven inflam-
matory disease such as RA.
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